These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy. Paton DM Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875 [TBL] [Abstract][Full Text] [Related]
9. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. Gertz M; Adams D; Ando Y; Beirão JM; Bokhari S; Coelho T; Comenzo RL; Damy T; Dorbala S; Drachman BM; Fontana M; Gillmore JD; Grogan M; Hawkins PN; Lousada I; Kristen AV; Ruberg FL; Suhr OB; Maurer MS; Nativi-Nicolau J; Quarta CC; Rapezzi C; Witteles R; Merlini G BMC Fam Pract; 2020 Sep; 21(1):198. PubMed ID: 32967612 [TBL] [Abstract][Full Text] [Related]
10. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
11. Therapy of ATTR Cardiac Amyloidosis: Current Indications. Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119 [TBL] [Abstract][Full Text] [Related]
12. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226 [TBL] [Abstract][Full Text] [Related]
13. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy. Galant NJ; Westermark P; Higaki JN; Chakrabartty A Clin Sci (Lond); 2017 Mar; 131(5):395-409. PubMed ID: 28213611 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of transthyretin amyloidosis cardiomyopathy: A position statement of the Polish Cardiac Society. Grzybowski J; Podolec P; Holcman K; Gawor-Prokopczyk M; Jankowska E; Kostkiewicz M; Dąbrowska-Kugacka A; Lipowska M; Mazurkiewicz Ł; Rajtar-Salwa R; Rubiś P; Straburzyńska-Migaj E; Szczygieł J; Mitkowski P Kardiol Pol; 2023; 81(11):1167-1185. PubMed ID: 37768101 [TBL] [Abstract][Full Text] [Related]
15. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620 [TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy. Vaishnav J; Brown E; Sharma K Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305 [TBL] [Abstract][Full Text] [Related]